On May 13-16, the China International Medicinal Equipment Fair (CMEF), the largest exhibition of medical equipment, related products, and services in the Asia-Pacific region, was held in Shanghai.

During this exhibition, Wondfo not only brought the blockbuster products, but also packages of application solutions of products in various scenarios such as emergency and severe cases, respiratory infectious disease, tumor, and COVID-19, attracting a lot of visitors to the booth for consultation.

Since the outbreak of COVID-19 in 2020, Wondfo has been working across the company and pouring resources into R&D to deliver products that help bring the pandemic under control.

Wondfo 2019-nCoV antibody test (lateral flow method), developed in Feb. 2020, is among the tests of this kind that initially got approved to the market in China. It is now widely recognized around the world, sold in more than 90 countries. Recently, the test has also been identified to be one of the top-performing POCTs that meet WHO TPP “desirable” criteria.

Wondfo 2019-nCoV Antibody Test (Lateral Flow Test)

As countries are facilitating COVID-19 screening, antigen rapid test is of great help. With a swab and a cassette, Wondfo 2019-nCoV antigen test (lateral flow method) delivers reliable results in 15 minutes. The test has received NMPA approval and CE marking and recently has been validated by medical regulatory bodies in many European countries, including Germany, France, Switzerland, Italy, Belgium, etc.

Wondfo 2019-nCoV Antigen Test (Lateral Flow Test)

Meanwhile, with a crying need for getting the pandemic under control quickly and allowing people to get back to normal, COVID-19 self-testing is being considered to be incorporated into national testing strategies program by more and more countries, such as Germany, France.

From a public health perspective, self-tests can improve the accessibility to testing by allowing laypeople to carry out the COVID-19 test at home or anywhere else easily. Self-testing could therefore enhance disease control with prompt identification and isolation of cases.

In April, Wondfo 2019-nCoV antigen test has been received special approval from the Germany BfArM for self-administration by laypersons for COVID-19 infection detection. The test can be used to complement professionally administered RT-PCR tests. With it, you can perform the COVID-19 test at the convenience of home, with trusted results in 15 minutes.

To meet different testing needs, Wondfo provides various packaging options: single test per box, 5 tests per box, and 20 tests per box.

Wondfo 2019-nCoV Antigen Test (Nasal Swab Self-Testing) - 20 tests per box

Besides the above, Wondfo has also developed an RT-PCR test kit that precisely targets ORF1ab and N protein of 2019-nCoV. The test provides more accurate results in about 60min after sample extraction.

Wondfo, founded in 1992, is the leader of China's point-of-care testing (POCT) industry. We now own multiple advanced technology platforms including immune colloidal gold, immunofluorescence, electrochemistry, dry biochemistry, chemiluminescence, molecular diagnostics, pathology, and have a wide range of products for the rapid identification of cardiovascular disease, inflammation, tumor, infectious disease, drug of abuse, pregnancy, etc. Our products are widely recognized in over 140+ countries.

Our commitment is to make the next breakthroughs in healthcare, providing communities worldwide with life-changing technology to ensure everybody's well-being.